Compare FOFO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | TPST |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Hong Kong | United States |
| Employees | 14 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 30.9M |
| IPO Year | N/A | 2012 |
| Metric | FOFO | TPST |
|---|---|---|
| Price | $2.37 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 60.1K | ★ 173.9K |
| Earning Date | 03-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $1.50 |
| 52 Week High | $68.00 | $12.22 |
| Indicator | FOFO | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 45.82 |
| Support Level | $2.34 | $1.57 |
| Resistance Level | $5.74 | $2.48 |
| Average True Range (ATR) | 0.31 | 0.15 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.73 | 35.19 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.